Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Daidzein from dietary supplement to a drug candidate: An evaluation of potential

Ubaid, Mohammed, Salauddin, Shadani, Md Andalib, Kawish, S. M., Albratty, Mohammed, Makeen, Hafiz A., Alhazmi, Hassan A., Najmi, Asim, Zoghebi, Khalid, Halawi, Maryam A., Ali, Abuzer, Alam, Md Shamsher, Iqbal, Zeenat and Mirza, Mohd. Aamir 2023. Daidzein from dietary supplement to a drug candidate: An evaluation of potential. ACS Omega 8 (36) , 32271 - 32293. 10.1021/acsomega.3c03741

[thumbnail of ubaid-et-al-2023-daidzein-from-dietary-supplement-to-a-drug-candidate-an-evaluation-of-potential.pdf] PDF - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB)


Daidzein (DDZ) is a well-known nutraceutical supplement belonging to the class of isoflavones. It is isolated from various sources such as alfalfa, soybean, and red clover. It demonstrates a broad array of pharmacological/beneficial properties such as cardiovascular exercise, cholesterol reduction, and anticancer, antifibrotic, and antidiabetic effects, which make it effective in treating a wide range of diseases. Its structure and operation are the same as those of human estrogens, which are important in preventing osteoporosis, cancer, and postmenopausal diseases. It is thus a promising candidate for development as a phytopharmaceutical. Addressing safety, efficacy, and physicochemical properties are the primary prerequisites. DDZ is already ingested every day in varying amounts, so there should not be a significant safety risk; however, each indication requires a different dose to be determined. Some clinical trials are already being conducted globally to confirm its safety, efficacy, and therapeutic potential. Furthermore, as a result of its therapeutic influence on health, in order to establish intellectual property, patents are utilized. In light of the vast potential of eugenol, this review presents a detailed data collection on DDZ to substantiate the claim to develop it in the therapeutic category.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: American Chemical Society
ISSN: 2470-1343
Date of First Compliant Deposit: 20 October 2023
Date of Acceptance: 18 July 2023
Last Modified: 26 Oct 2023 11:45

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics